HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells

• Anthony Kong,

  Affiliations Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom, Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom

  ⨯
• Véronique Calleja,

  Affiliation Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom

  ⨯
• Pierre Leboucher,

  Affiliation Laboratoire de Physiologie de la Perception et de l'Action, College de France, Paris, France

  ⨯
• Adrian Harris,

  Affiliation Weatherall Institute of Molecular Medicine (IMM), Cancer Research UK, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

  ⨯
• Peter J. Parker,

  Affiliations Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom, Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London, United Kingdom

  ⨯
• Banafshé Larijani

  * E-mail: banafshe.larijani@cancer.org.uk

  Affiliation Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom

  ⨯